{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:35Z","timestamp":1787261015124,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101238","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:29:00Z","timestamp":1784302140000},"page":"101238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Severe primary organ-related complications in patients with de novo metastatic cancer: implications for prophylactic local therapy"],"prefix":"10.1016","volume":"60","author":[{"given":"Hefei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Merhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naia","family":"Tabakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karishma","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Christodouleas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctro.2026.101238_bb0005","doi-asserted-by":"crossref","DOI":"10.3892\/mco.2021.2472","volume":"16","author":"Hamed","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"10162","key":"10.1016\/j.ctro.2026.101238_bb0010","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctro.2026.101238_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.6004\/jnccn.2018.7013","article-title":"Clinical impact of local progression in pancreatic cancer","volume":"16","author":"Cardillo","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"10.1016\/j.ctro.2026.101238_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36604","article-title":"Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy","volume":"6","author":"Corsini","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.ctro.2026.101238_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19524","article-title":"Survival trends in urothelial cancer before and after ICIs and antibody drug conjugates","volume":"8","author":"Lian","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.ctro.2026.101238_bb0030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"10467","key":"10.1016\/j.ctro.2026.101238_bb0035","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctro.2026.101238_bb0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/COC.0000000000000305","article-title":"Comparison of demographics, tumor characteristics, and survival between pancreatic adenocarcinomas and pancreatic neuroendocrine tumors: a population-based study","volume":"41","author":"Yadav","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101238_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4097\/kja.d.18.00067","article-title":"Survival analysis: part I \u2014 analysis of time-to-event","volume":"71","author":"In","year":"2018","journal-title":"Korean J Anesthesiol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101238_bb0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.6004\/jnccn.2018.7111","article-title":"A population-based study of morbidity after pancreatic cancer diagnosis","volume":"17","author":"Sarkar","year":"2019","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:25:00Z","timestamp":1787257500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"alternative-id":["S2405630826001333"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101238","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe primary organ-related complications in patients with de novo metastatic cancer: implications for prophylactic local therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101238"}}